Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.
Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Malaysia.
Int J Mol Sci. 2021 Nov 17;22(22):12421. doi: 10.3390/ijms222212421.
The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.
SARS-CoV-2 病毒的快速突变目前是一个主要关注点，尚无有效的药物和治疗方法。疾病的严重程度与细胞因子风暴的诱导有关，细胞因子风暴会促进肺部广泛炎症，导致许多急性肺损伤、肺水肿，最终导致死亡。间充质干细胞（MSCs）可能被证明是一种治疗选择，因为它们具有免疫调节和再生特性。利用 MSCs 治疗急性肺损伤（ALI）或急性呼吸窘迫综合征（ARDS）的临床试验为治疗 COVID-19 后患者提供了基础。在这篇综述中，我们讨论了 MSCs 作为免疫调节剂的作用，以降低 COVID-19 患者的严重程度和死亡率，包括将 MSCs 用作 COVID-19 后患者的替代再生疗法。这篇综述还包括利用 MSCs 的当前临床试验及其在长期 COVID 治疗中的潜在未来应用。
